Abstract:Hepatitis B virus is an important health problem which about 400 million people are infected chronically and 500,000 to 1,200,000 people die every year due to HBVrelated diseases. In the study we aimed to investigate the HBV DNA results in HBsAg positive patients. HBsAg positivity was detected by ELISA method in patients who were admitted to our hospital with suspicion of hepatitis. HBV DNA was performed by real time PCR. In this context, the presence of HBV DNA in serum sample results of 2437 HBsAg-positive p… Show more
“…It is interesting to note that all four HBsAg-positive patients were HBV DNA negative, which supports the idea that there is no correlation between HBsAg positivity and HBV DNA. [21][22][23] The prevalence of occult HBV infection has been studied in different parts of the world and among various groups; however, there are conflicting with results even in a similar group. As an illustration, OBI prevalence among hemodialysis patients was 1.5% (Turkey), 24 0.5% (Iran), 25 0% (Germany), 26 1.3% (Japan), 27 and 0% (Italy) 28 ; in hemophilia patients was 1.73% in Pakistan, 29 9.3% in Iran, 30 and 0% in Polish 31 ; among thalassemia patients was 31.4% (India), 6 32.5% (Egypt), 5 and 0% (Iran) 13,14 ; in individuals with HCC was 30% (Japan), 32 38.5% (Korea), 33 50% (Egypt), 34 and 70.4% (China) 35 ; among blood donors in different parts of the world was 3.7% (Egypt), 36 4.71% (India), 37 1.98% (Colombia), 38 0.3% (Lebanon), 39 0% (Iran), 8 and 7.4% (Libya).…”
Occult Hepatitis B Infection (OBI) is a critical risk factor for triggering post-transfusion hepatitis (PTH), cirrhosis, hepatocellular carcinoma, and hepatitis B virus (HBV) reactivation, which β-thalassemia major (BTM) patients are at risk of it due to multiple blood transfusions. This study was aimed at determining the prevalence of OBI among BTM patients from Khuzestan Province, Iran. In this cross-sectional study, 90 thalassemia patients, who have received blood 36 to 552 times, participated referred to the Shafa hospital of Ahvaz city from January 2018 to April 2019. ELISA for determining serological markers (HBsAg, anti-HBc, anti-HBs, and anti-HCV) and real-time PCR for detecting HBV-DNA were performed; Nested PCR was conducted for DNA sequencing and determining the genotype of OBI case. Phylogenetic and statistical analyses were done by R package. Of 90 subjects enrolled in this study; 95.5% (86/90) were HBsAg negative, and the frequency of OBI among them was 1.16% (1/86). The anti-HBs, anti-HBc, and anti-HCV were detected in 80.00%, 7.78%, and 12.2% of patients, respectively. HBV-DNA was assessed at four HBsAg-positive subjects as well, and all of them were negative. The phylogenetic analysis showed that the detected HBV DNA in the OBI case belongs to the genotype D. This research, for the first time, demonstrated that OBI is present among β-thalassemia patients in Iran. Also, further studies are necessary to determine the actual prevalence of OBI among BTM patients in Iran to decisions concerning OBI screening, especially in transfusion centers.
“…It is interesting to note that all four HBsAg-positive patients were HBV DNA negative, which supports the idea that there is no correlation between HBsAg positivity and HBV DNA. [21][22][23] The prevalence of occult HBV infection has been studied in different parts of the world and among various groups; however, there are conflicting with results even in a similar group. As an illustration, OBI prevalence among hemodialysis patients was 1.5% (Turkey), 24 0.5% (Iran), 25 0% (Germany), 26 1.3% (Japan), 27 and 0% (Italy) 28 ; in hemophilia patients was 1.73% in Pakistan, 29 9.3% in Iran, 30 and 0% in Polish 31 ; among thalassemia patients was 31.4% (India), 6 32.5% (Egypt), 5 and 0% (Iran) 13,14 ; in individuals with HCC was 30% (Japan), 32 38.5% (Korea), 33 50% (Egypt), 34 and 70.4% (China) 35 ; among blood donors in different parts of the world was 3.7% (Egypt), 36 4.71% (India), 37 1.98% (Colombia), 38 0.3% (Lebanon), 39 0% (Iran), 8 and 7.4% (Libya).…”
Occult Hepatitis B Infection (OBI) is a critical risk factor for triggering post-transfusion hepatitis (PTH), cirrhosis, hepatocellular carcinoma, and hepatitis B virus (HBV) reactivation, which β-thalassemia major (BTM) patients are at risk of it due to multiple blood transfusions. This study was aimed at determining the prevalence of OBI among BTM patients from Khuzestan Province, Iran. In this cross-sectional study, 90 thalassemia patients, who have received blood 36 to 552 times, participated referred to the Shafa hospital of Ahvaz city from January 2018 to April 2019. ELISA for determining serological markers (HBsAg, anti-HBc, anti-HBs, and anti-HCV) and real-time PCR for detecting HBV-DNA were performed; Nested PCR was conducted for DNA sequencing and determining the genotype of OBI case. Phylogenetic and statistical analyses were done by R package. Of 90 subjects enrolled in this study; 95.5% (86/90) were HBsAg negative, and the frequency of OBI among them was 1.16% (1/86). The anti-HBs, anti-HBc, and anti-HCV were detected in 80.00%, 7.78%, and 12.2% of patients, respectively. HBV-DNA was assessed at four HBsAg-positive subjects as well, and all of them were negative. The phylogenetic analysis showed that the detected HBV DNA in the OBI case belongs to the genotype D. This research, for the first time, demonstrated that OBI is present among β-thalassemia patients in Iran. Also, further studies are necessary to determine the actual prevalence of OBI among BTM patients in Iran to decisions concerning OBI screening, especially in transfusion centers.
“…More than 350 million people worldwide have chronic HBV 3 . And annually about 500,000 -1200,000 people die from various HBV-related illnesses, and on average, 5% of people infected with acute hepatitis B become chronic 4 . The risk of developing chronic infections in children under the age of one year reaches 90% and about 25% of them die before adolescence due to cancer and liver cirrhosis 5 .…”
Section: Introductionmentioning
confidence: 99%
“…Real time PCR is a simple and fast that allows the quantification of viral DNA 4 . The aim of this study is to investigate the presence of hepatitis B virus DNA by Real-time PCR in HBsAg positive patients and the risk factor for HBV activation among HbsAg positive patients.…”
Background: Hepatitis B virus (HBV) infections are one of the world's health problems that annually kill about 500,000 to 1,200,000 people. Investigation of HBV DNA in the person infected with HBV is a definitive indicator of activation and replication of HBV.Objectives: The aim of this study is to investigate the DNA of HBV in HBsAg positive patients and to study the risk factors for virus activation. Methods: This study was conducted on 106 HBsAg positive patients from January 2020 to July 2020 in Kabul. After informed consent, 3 to 5 milliliters of blood was collected for the HBV-DNA testing using the Real-time PCR method.Result: Out of 106 HbsAg positive patients, 74 (69.8%) were males and 32 (30.2%) females. The patients were aged between 11 and 65 years. Hepatitis B virus DNA was positive in 58 (54.7%) of the samples, 41 (70.7%) were male and 17 (29.3%) were female. The viral DNA load was in the range of 9.85 x 102 to 9.3 x 108 copies/ ml. Most of the patients were aged between 20 and 30 years. Conclusion: From 106 HbsAg positive patients, 23(39.7%) were in the age group of 20 – 30 years, and males were more infected than females. The majority of the patients were married and had an informal job with education below grade 12. No specific differences were found in the availability of HBV DNA between patients who received hepatitis B treatment before and those who did not.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.